Supplemental Table S7. Reverse Phase Protein Array (RPPA) data. Total protein and phosphorylation levels in untreated and treated A673 and TC32 cells are normalized to total protein levels in each sample.

Supplemental Table S6. Muliple metrics were used to calculate synergy of all compounds tested from MIPE 4.0 library in combination with PF-562271. Highlighted in green are Pan-Aurora Inhibitors, red are Aurora B inhibitors, and blue are Aurora A inhibitors.

Supplemental Table S2. Target sequences for shRNAs targeting AURKB expression in the Achilles Project

Supplemental Table S5. Target sequences for shRNAs targeting AURKB and EWS/FLI expression

Supplemental Methods and Figures Supplemental Figure S1. Aurora kinase expression in Ewing sarcoma Supplemental Figure S2. Effects of cell growth on response to AZD-1152 as a function of duration of treatment. Supplemental Figure S3. Aurora kinase and FAK inhibitor combinations are synergistic in Ewing sarcoma cell lines Supplemental Figure S4. Response of Ewing cell lines treated with combinations of Aurora kinase and FAK inhibitors Supplemental Figure S5. Cell cycle and apoptotic effects of Aurora kinase B knock out in Ewing sarcoma cell lines Supplemental Figure S6. PYK2 is poorly expressed in Ewing sarcoma cells Supplemental Figure S7. Zebrafish and Murine studies